Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine

Current Treatment Options in Cardiovascular Medicine

Volumn 18, Issue 2, 2016, Pages 1-15

  Kitai, Takeshi ^a,b   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Clinical trials; Heart failure; Heart rate; Heart rate reduction; Ivabradine

Indexed keywords

EID: 84957547582     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-015-0435-5     Document Type: Review

References (80)

1. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
2. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992;340:88–92.
3. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study. Lancet. 2010;376:875–85. This landmark randomized trial of ivabradine in patients with heart failure confirmed the substudy findings of BEAUTIFUL in that it only included those with a heart rate above 70 bpm and found reduced cardiac events. The reduction in events was largely due to reduced heart failure hospitalizations and heart failure death.
4. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (beautiful): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16. This randomized trial found that ivabradine did not reduce mortality and cardiac events in patients with stable coronary artery disease and left ventricular systolic dysfunction, but appeared to be effective in the subgroup with a heart rate above 70 bpm.
5. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (shift): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886–94. This substudy of the SHIFT trial found that patients with highest heart rates (≥87 bpm) were at more than twofold higher risk for cardiac events than were patients with the lowest heart rates (<72 bpm). The risks of cardiac events increased by 3 % with every beat increase from baseline heart rate and 16 % for every 5-bpm increase.
6. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol. 1997;30:1104–6.
7. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823–30.
8. Fosbol EL, Seibaek M, Brendorp B, Moller DV, Thune JJ, Gislason GH, et al. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the diamond study. Int J Cardiol. 2010;140:279–86.
9. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428–33.
10. Ahmadi-Kashani M, Kessler DJ, Day J, Bunch TJ, Stolen KQ, Brown S, et al. Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation. 2009;120:2040–5.
11. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589–95.
12. de Groote P, Isnard R, Assyag P, Clerson P, Ducardonnet A, Galinier M, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007;9:1205–11.
13. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–74.
14. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743–50.
15. Tanaka N, Nozawa T, Yasumura Y, Futaki S, Hiramori K, Suga H. Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990;40:503–21.
16. van den Wijngaard JP, Kolyva C, Siebes M, Dankelman J, van Gemert MJ, Piek JJ, et al. Model prediction of subendocardial perfusion of the coronary circulation in the presence of an epicardial coronary artery stenosis. Med Biol Eng Comput. 2008;46:421–32.
17. Hoppe UC, Jansen E, Sudkamp M, Beuckelmann DJ. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. Circulation. 1998;97:55–65.
18. Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace. 2010;12:261–5.
19. Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, Just H. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J. 1994;15:164–70.
20. Kurita T, Onishi K, Dohi K, Tanabe M, Fujimoto N, Tanigawa T, et al. Impact of heart rate on mechanical dyssynchrony and left ventricular contractility in patients with heart failure and normal QRS duration. Eur J Heart Fail. 2007;9:637–43.
21. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674–9.
22. Adabag AS, Grandits GA, Prineas RJ, Crow RS, Bloomfield HE, Neaton JD. Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men. Am J Cardiol. 2008;101:1437–43.
23. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55.
24. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
25. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
26. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.
27. Gullestad L, Wikstrand J, Deedwania P, Hjalmarson A, Egstrup K, Elkayam U, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2005;45:252–9.
28. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26:2259–68.
29. Gelbrich G, Edelmann F, Inkrot S, Lainscak M, Apostolovic S, Neskovic AN, et al. Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. Int J Cardiol. 2012;155:160–6.
30. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–94.
31. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865–9.
32. Tandon P, McAlister FA, Tsuyuki RT, Hervas-Malo M, Dupuit R, Ezekowitz J, et al. The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch Intern Med. 2004;164:769–74.
33. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature. 1979;280:235–6.
34. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120:1–13.
35. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106:434–46.
36. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757–65. Comprehensive review of the mechanisms of action of ivabradine.
37. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–55.
38. Musialek P, Casadei B. Nitrovasodilators and heart rate: more than the arterial baroreflex. Cardiovasc Res. 2000;47:404–5.
39. Musialek P, Lei M, Brown HF, Paterson DJ, Casadei B. Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current, I(f). Circ Res. 1997;81:60–8.
40. Musialek P, Rigg L, Terrar DA, Paterson DJ, Casadei B. Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors. J Mol Cell Cardiol. 2000;32:1831–40.
41. Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010;333:191–201.
42. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–23.
43. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112:37–42.
44. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051–7.
45. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–66.
46. Bel A, Perrault LP, Faris B, Mouas C, Vilaine JP, Menasche P. Inhibition of the pacemaker current: a bradycardic therapy for off-pump coronary operations. Ann Thorac Surg. 1998;66:148–52.
47. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1997;96:2197–205.
48. Stillitano F, Lonardo G, Zicha S, Varro A, Cerbai E, Mugelli A, et al. Molecular basis of funny current (if) in normal and failing human heart. J Mol Cell Cardiol. 2008;45:289–99.
49. Cerbai E, Sartiani L, DePaoli P, Pino R, Maccherini M, Bizzarri F, et al. The properties of the pacemaker current I(f) in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol. 2001;33:441–8.
50. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284:H676–82.
51. Miyamoto Y, Higuchi J, Abe Y, Hiura T, Nakazono Y, Mikami T. Dynamics of cardiac output and systolic time intervals in supine and upright exercise. J Appl Physiol Respir Environ Exerc Physiol. 1983;55:1674–81.
52. Dedkov EI, Zheng W, Christensen LP, Weiss RM, Mahlberg-Gaudin F, Tomanek RJ. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol. 2007;293:H590–8.
53. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101:689–94.
54. Seitelberger R, Guth BD, Heusch G, Lee JD, Katayama K, Ross Jr J. Intracoronary alpha 2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res. 1988;62:436–42.
55. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–9. In this trial, ivabradine failed to affect the primary end point of death from cardiovascular causes of nonfatal myocardial infarction in patients with stable coronary artery disease without clinical HF and a HR of ≥70 bpm.
56. Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006;572:335–46.
57. Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33:2813–20.
58. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395–404.
59. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–9.
60. Tavazzi L, Swedberg K, Komajda M, Bohm M, Borer JS, Lainscak M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;170:182–8.
61. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. 2009;103:295–300.
62. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37:1950–6.
63. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26:447–62.
64. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective. Heart. 2014;100:1031–6.
65. Kourlaba G, Parissis J, Karavidas A, Beletsi A, Milonas C, Branscombe N, et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Serv Res. 2014;14:631.
66. Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S, et al. Impact of “off-label” use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15:349–55.
67. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.
68. Greener ID, Monfredi O, Inada S, Chandler NJ, Tellez JO, Atkinson A, et al. Molecular architecture of the human specialised atrioventricular conduction axis. J Mol Cell Cardiol. 2011;50:642–51.
69. Fox K, Komajda M, Ford I, Robertson M, Bohm M, Borer JS, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34:2263–70.
70. Lefroy DC, Fang JC, Stevenson LW, Hartley LH, Friedman PL, Stevenson WG. Recipient-to-donor atrioatrial conduction after orthotopic heart transplantation: surface electrocardiographic features and estimated prevalence. Am J Cardiol. 1998;82:444–50.
71. Lage-Galle E, Romero-Rodriguez N, Nevado-Portero J, Guisado-Rasco A, Sobrino-Marquez M, Machuca MG, et al. Safety and effectiveness of ivabradine after cardiac transplantation. Transplant Proc. 2010;42:3191–2.
72. Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, et al. Heart rate reduction after heart transplantation with beta-blocker versus the selective if channel antagonist ivabradine. Transplantation. 2007;84:988–96.
73. Doesch AO, Ammon K, Konstandin M, Celik S, Kristen A, Frankenstein L, et al. Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation. 2009;88:835–41.
74. Zhang R, Haverich A, Struber M, Simon A, Pichlmaier M, Bara C. Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol. 2008;97:811–9.
75. Link A, Reil JC, Selejan S, Bohm M. Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clin Res Cardiol. 2009;98:513–5.
76. Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L. Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol. 2010;99:853–5.
77. Sargento L, Satendra M, Longo S, Lousada N, dos Reis RP. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure. Am J Cardiovasc Drugs. 2014;14:229–35.
78. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117:686–97.
79. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683–91.
80. Gallet R, Ternacle J, Damy T, Guendouz S, Bremont C, Seemann A, et al. Hemodynamic effects of ivabradine in addition to dobutamine in patients with severe systolic dysfunction. Int J Cardiol. 2014;176:450–5.